about
AcromegalyAcromegaly pathogenesis and treatmentProlactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Management of acromegaly in Latin America: expert panel recommendationsNovel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of actionGrowth hormone tumor histological subtypes predict response to surgical and medical therapy.Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.Medical therapy of acromegalyThe role of growth hormone-receptor antagonism in relation to acromegaly.A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumorsCurrent pharmacotherapy for acromegaly: a review.Growth hormone and its disordersEtiologic aspects and management of acromegaly.Recent developments in the therapy of acromegaly.Resistance to somatostatin analogs in acromegaly: an evolving concept?Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.Pegvisomant in acromegaly: why, when, how.Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Somatostatin agonists for treatment of acromegaly.A consensus on the diagnosis and treatment of acromegaly complications.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Multimodality treatment for invasive pituitary adenomas.Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) studyThe somatostatin receptor subtype 5 in neuroendocrine tumours.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsInvestigational therapies for acromegaly.Acromegaly: Beyond surgeryEmerging drugs for acromegaly.Update on prognostic factors in acromegaly: Is a risk score possible?Adverse events associated with somatostatin analogs in acromegaly.New therapeutic agents for acromegaly.Current and future medical treatments for patients with acromegaly.Discontinuation of somatostatin analogs while acromegaly is in long-term remission.In situ maleimide bridging of disulfides and a new approach to protein PEGylation.Protein modification, bioconjugation, and disulfide bridging using bromomaleimides.The role of apoptosis in pituitary adenomas in the field of conventionally used therapeutic approaches.Acromegaly: role of surgery in the therapeutic armamentarium.Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.
P2860
Q21202912-6A0781B5-84FB-482E-B9F9-9707F9700D2CQ24647360-4718BCC3-0217-4450-AEC8-C7C584B88364Q33579615-FFE32AD7-0432-46B6-BEF0-9BC51FF668A2Q33772673-5039B758-8244-4E4D-AA85-51FAB450A8A7Q33794388-E87D65EC-7BAF-46B7-A51A-6EE3BF3511ADQ35087618-C8DF38B9-DEAE-4989-A6D8-C860D4FC5F7FQ35091578-82663C73-5C69-4210-A013-D5C3A0F085F4Q35684886-A8CF8553-BFEF-49C7-A26F-C70F83762623Q35895856-873F25A5-F0D4-44E3-AB57-B673C0803A1BQ35925517-05F927B3-5060-484B-BD4B-526FF95B9723Q35987499-E93C4CA8-AA21-4216-8D6F-CB59B7C54989Q36270932-BB43704A-B24A-4C25-BEBE-018EE993877DQ36301564-1C96AFF1-0FAB-4A40-BF56-4761D813F4DAQ36362200-BF6F8240-E84A-47D8-87B2-FC6F57DA5EA6Q36380875-3538CF4A-AE00-40B2-915F-BB633BFB57FEQ36407309-E8BF7E81-DE0A-48AE-BCD7-1653BF47B9CFQ36428225-C45A380C-9179-4421-9E0D-26D6ED045028Q36611703-3E4B031D-3D05-44FE-ACBF-FAEBB5C63009Q36965612-51492934-EBAB-4E4C-8710-6573A187B9C9Q37029532-2F91ED8E-68BC-435B-985A-C3AF6FBC88CCQ37055643-4D4C163D-44CD-41CB-9D74-3BDA2B3DACA4Q37061155-6FE2E8B8-18E9-497B-9784-C2997033A573Q37321948-4E6464D0-4264-4B72-9375-E24FA6E2AF19Q37427263-1F6E858C-114A-441C-B7EC-8AA2C8315DD4Q37578420-4B93EA72-33A7-435E-B192-1F494D06726BQ37691450-CFAACBB6-E0FA-4960-8C0E-85897AF228E1Q37980741-281CE9D5-4C3F-4E64-B816-E665754D2DD5Q38111437-EE3A24DF-CAA2-461D-A553-ECFF07C722B7Q38130271-8C48403A-39BE-47CB-B4FA-F9D353E8972BQ38176659-3A5F6B3D-83F9-454B-A82D-047E0DA6A7C8Q38214473-ABC5B5A3-8973-4436-A625-C33E93EE3AF2Q38548973-E767C9E9-EA30-4E82-96AE-AF3F5A717523Q38648739-6FB72137-7A28-44DA-AF64-FA507E36A4C3Q38847622-83A31123-A31D-4C27-9AB9-17FD6F7920ABQ39116087-3A7DD1A3-03C5-4313-9352-68E53A433B0FQ39602014-D12EC8ED-1E1E-4A92-B770-764BEA35E439Q39707456-AA0E0DF1-8E13-423C-8CCC-E5335B148BCDQ40576073-80FA144C-5F7D-40AB-8B59-3F32A5880EDDQ41628092-F8EB3743-597B-44CF-91A3-4D18321CEC5DQ43222345-C7A706AF-2923-427D-A855-5F0EA7243BA0
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Somatostatin analogs in acromegaly.
@ast
Somatostatin analogs in acromegaly.
@en
Somatostatin analogs in acromegaly.
@nl
type
label
Somatostatin analogs in acromegaly.
@ast
Somatostatin analogs in acromegaly.
@en
Somatostatin analogs in acromegaly.
@nl
prefLabel
Somatostatin analogs in acromegaly.
@ast
Somatostatin analogs in acromegaly.
@en
Somatostatin analogs in acromegaly.
@nl
P356
P1476
Somatostatin analogs in acromegaly.
@en
P2093
Pamela U Freda
P304
P356
10.1210/JCEM.87.7.8665
P407
P577
2002-07-01T00:00:00Z